Osteochondral lesions of the talus
Conditions
Interventions
Experimental group:Repair talus cartilage defect with medical collagen
Control group:Subchondral bone drilling to repair cartilage defects
Sponsors
920th Hospital of the Chinese People's Liberation Army Joint Logistic Support Force
Eligibility
Sex/Gender
All
Age
18 Years to 55 Years
Inclusion criteria
Inclusion criteria: 1. No gender limitation, aged 18-55 years. 2. Acute or chronic talus cartilage injury caused by trauma or exudative osteochonitis, with injury area between 2.0 ~ 4.0 cm^2. 3. Before the study, the subjects were willing and able to sign the informed consent. 4. Patient is willing to cooperate closely with the strict postoperative rehabilitation procedures established by the doctors. 5. Patient is willing to cooperate with the whole treatment process, and is willing to bear the corresponding consequences or complications caused by the treatment process, as well as the corresponding postoperative treatment measures. 6. According to the judgment of the researcher, the subjects can understand the clinical study and cooperate to complete the whole study process. 7. Subjects can read, express and understand the content of the study plan, and provide feedback information in appropriate language.
Exclusion criteria
Exclusion criteria: 1. Patient was obese, with a BMI index of >= 30 kg/m^2. 2. X-leg or O-leg. 3. Known history of immune system disease that causes joint and meniscus damage. 4. Severe arthritis with extensive damage to the articular cartilage, cannot be treated with this technique. 5. Severe heart, liver, kidney and lung insufficiency. 6. Pregnant women and lactating women. 7. Known HIV-infected persons. 8. Bacterial infection of the ankle joint cavity or septic arthritis. 9. Patients with severe primary diseases or mental diseases such as metabolic disorders, immune dysfunction, hematopoietic system, endocrine system, etc., such as coagulation disorders, severe diabetes, drug abuse, etc. 10. Poor compliance, such as unwilling or inability to limit activities, follow doctor's orders, and fail to follow up on time. 11. To participate in another clinical study within 6 months. 12. Suffering from diseases that the researchers believe may affect their participation in this study, such as mental disorders, alcohol or drug addiction, malignant or serious illness, etc. 13. Subjects with severe neurological or musculoskeletal diseases, such as myasthenia gravis, muscular dystrophy, cerebral infarction, cerebral palsy, etc. 14. Subjects cannot express, read and understand the content of the research protocol, and cannot provide feedback in appropriate language. 15. The subject has other diseases and the life expectancy is less than 2 years. 16. Subjects are participating in other clinical trials and have not reached the endpoint. 17. Other patients considered by the investigator to be unsuitable to participate in this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| MRI;AROM (active range of motion); | — |
Countries
China
Contacts
Public ContactTan Hongbo
920th Hospital of Joint Logistic Support Force
Outcome results
None listed